Immunotherapy · 2016 · 25 citations · 33 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyCancer VaccinesCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmunotherapy For Brain TumorsAntigen Presenting CellsCancer Vaccine ResponsesCancer Vaccine T-cell ResponsesGlioblastoma ImmunologyGlioblastoma ImmunotherapyImmune Cell ActivationImmune Checkpoint Inhibitor TherapyImmunotherapy Trials
There are over 400 ongoing clinical trials using tumor-derived vaccines. This approach is especially attractive for many types of brain tumors, including glioblastoma, yet so far the clinical response is highly variable. One contributor to poor response is CD200, which acts as a checkpoint blockade, inducing immune tolerance. We demonstrate that, in response to vaccination, glioma-derived CD200 suppresses the anti-tumor immune response. In contrast, a CD200 peptide inhibitor that activates antigen-presenting cells overcomes immune tolerance. The addition of the CD200 inhibitor significantly increased leukocyte infiltration into the vaccine site, cytokine and chemokine production, and cytolytic activity. Our data therefore suggest that CD200 suppresses the immune system's response to vaccines, and that blocking CD200 could improve the efficacy of cancer immunotherapy.
33
Down-Regulation of the Macrophage Lineage Through Interaction with OX2 (CD200)
Robert M. Hoek, Sigrid R. Ruuls, Craig A. Murphy et al. · Science · 2000 · 1K citations